Physician profile
Eduardo Weiss
NPI 1053308965
$384,334.91
in general payments reported to CMS, 2019-2025
61 companies · $20K in 2025
The $20K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $36K · 2021: $86K · 2022: $104K · 2023: $44K · 2024: $30K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $13K · Consulting Fee: $3,938 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,944.04 |
| Food and Beverage | $13,413.22 |
| Consulting Fee | $3,937.50 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229,111.41 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Allergan, INC. | $110,436.89 | 2019-2022 | |
| Galderma Laboratories, L.P. | $24,524.43 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Avita Medical Americas, LLC | $2,337.50 | 2023 | Recell |
| Janssen Biotech, INC. | $1,890.79 | 2019-2025 | Tremfya |
| Genzyme Corporation | $1,784.01 | 2020-2025 | |
| Pfizer INC. | $1,274.09 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,214.71 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,204.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,080.47 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $924.36 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $849.05 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Merz North America, INC. | $785.46 | 2019-2020 | |
| Ucb, INC. | $633.14 | 2020-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $549.62 | 2021-2025 | Opzelura |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $542.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.34 | 2022-2025 | Spevigo |
| Kerecis Limited | $525.28 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $487.48 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Lilly USA, LLC | $410.95 | 2020-2024 | Taltz, Ebglyss |
| Organogenesis INC. | $371.74 | 2019-2025 | Cygnus Dual, Affinity |
| Janssen Scientific Affairs, LLC | $256.34 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $253.78 | 2023-2024 | Vtama |
| Fresenius Kabi USA, LLC | $233.95 | 2023 | Idacio |
| Journey Medical Corporation | $214.26 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $205.66 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $191.72 | 2020-2021 | |
| Convatec INC. | $175.79 | 2023-2025 | |
| Botanix Sb INC | $159.52 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $149.54 | 2019-2020 | |
| Epi Health, LLC | $138.02 | 2022 | |
| Celgene Corporation | $136.87 | 2019 | |
| Revance Therapeutics, INC. | $121.15 | 2024 | Daxi |
| Biofrontera INC. | $117.65 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Misonix INC | $66.27 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $63.39 | 2023-2024 | |
| Paratek Pharmaceuticals, INC. | $61.20 | 2021-2023 | Nuzyra |
| Amgen INC. | $39.20 | 2020-2022 | |
| Smith+Nephew, INC. | $38.57 | 2019-2020 | |
| Sandoz INC. | $34.09 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $29.06 | 2021 | |
| Organon LLC | $29.04 | 2025 | |
| Icad, INC | $25.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.82 | 2019 | |
| Almirall LLC | $22.26 | 2021 | |
| Krystal Biotech INC | $19.15 | 2025 | Vyjuvek |
| Promius Pharma LLC | $18.06 | 2019 | |
| Merck Sharp & Dohme LLC | $17.36 | 2019 | |
| Tempus Ai, INC | $16.62 | 2024 | Merlin Test |
| Mayne Pharma Commercial LLC | $4.16 | 2023 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,181.57 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.